ARTICLE | Clinical News
Lexgenleucel-T: Phase I/II data
February 22, 2010 8:00 AM UTC
Data from an ongoing, U.S. Phase I/II trial showed that VRX496 led to a decrease in viral load in 7 of 8 evaluable HIV-1 infected patients fully suppressed on antiretroviral treatments who underwent s...